Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Amaryl-M 2/500 mg; Drug: Amaryl-M 1/500 mg

• Registration Number: NCT00934817
• Lead Sponsor: Handok Inc.

Brief Summary

The pharmacokinetics of glimepiride and metformin HCl will be compared after single dose intake of both combinations in order to answer the following questions:

* Is Amaryl-M 1/500 mg (Test tablet) proportional to Amaryl-M 2/500 mg tablet with regard to the glimepiride component?

* Is Amaryl-M 1/500 mg (Test tablet) tolerable comparing with Amaryl-M 2/500 mg?

Detailed Description

16 subjects were randomized to each of 2 sequence groups which have different treatment order of the study drug in each period.

Only healthy volunteers had screening tests such as medical inquiry, physical examination, clinical laboratory test, etc. within 4 weeks (-28d \~ -1d) prior to drug administration (1d) and those determined eligible for this study were selected and randomized between screening and 1 day prior to the first administration of study medication (-1d). Then, the subjects were admitted to the clinical research center of Seoul National University Hospital by 9 p.m. of -1d and then, they were not allowed to take anything except water.

After one week of washout period, subjects went on to the second phase of treatment period and were administered according to the treatment order in a crossover way. For the subjects who completed the study, post-study visit tests were performed after a designated time had passed.

Study Timeline

• Study Start: 2007-03
• Primary Completion: 2007-05
• Study Completion: 2007-08
• Status Verified: 2009-07
• Study First Submitted: 2009-07-06
• Study First Submitted QC: 2009-07-07
• Last Update Submitted: 2009-07-07
• Study First Posted: 2009-07-08
• Last Update Posted: 2009-07-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Age: Between 19 to 45 years of age, inclusive (age based on the date to give the informed consent)
• Ideal body weight (Broca index): between 50 to 90 kg, inclusive, and within ±20 % of Ideal Body Weight, [(Height in cm-100)×0.9]
• Subjects who are appropriate to participate in this study judged from clinical laboratory and physical examinations taken within 4weeks prior to the start of study
• Subjects who are able to abstain from caffeine or caffeine-containing products (e.g., coffee, cola, tea, chocolate), grapefruit and grapefruit containing products, alcohol and smoking within 7 days before dosing and during the hospitalization
• Subjects who give their informed consent voluntarily to participate in the study

Exclusion Criteria

• History of allergies including drug allergy, except untreated, asymptomatic, seasonal allergies at the time of dosing
• Use any medication not considered acceptable by the clinical investigator during the last 10 days period before the start day of the study
• Use of any inducer or inhibitors of metabolizing enzymes during the last 28 days before the start day of the study.
• History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease
• History of a significant surgical resection of gastrointestinal tract except appendectomy
• Abnormal clinical laboratory findings, especially for AST or ALT > 1.25 fold, total bilirubin > 1.5 fold of upper normal level
• Pregnant or lactating woman or woman of childbearing potential without medically acceptable birth control during the study
• Evidence of alcohol abuse (defined as regular alcohol intake that exceeds 24 oz [675 ml] of beer, 12 oz [340 ml] of wine or 160 ml of soju or 3 oz [85 ml] hard liquor per day [e.g., brandy, whiskey, gin]) or drug abuse
• Heavy smokers (> 10 cigarettes per day), or can't quit smoking during hospitalization
• Participation in clinical trials of any drug within 3 months prior to the start of study
• Donation of 200ml of whole blood within 4 weeks or 400ml within 12 weeks prior to the start of study
• Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or HIV antibody
• Judged to be inappropriate for the study by the investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
TR sequential group	Amaryl-M 1/500 mg	Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
TR sequential group	Amaryl-M 2/500 mg	Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
RT sequential group	Amaryl-M 2/500 mg	Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
RT sequential group	Amaryl-M 1/500 mg	Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2

Primary Outcome Measures

Name	Time	Method
Plasma drug concentrations of glimepiride and metformin, PK parameters: AUCt, AUCinf, Cmax, Tmax, T1/2	pre-dose (= 1d 0h), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 30 hrs after drug administration

Secondary Outcome Measures

Name	Time	Method
Physical examination, clinical laboratory tests	Screening, 2 day, 9 day, 13-15 day
Vital sign	screening, 1 day, 2 day, 8 day, 9 day, 13-15 day
Adverse event	1 day, 2 day, 8 day, 9 day, 13-15 day